Christopher Flowers, MD, MS

Articles by Christopher Flowers, MD, MS

Polatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.

Polatuzumab Vedotin Regimen Yields ‘Meaningful’ Benefit in DLBCL, Expert Says

April 19th 2023

Polatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.

The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer Patient

ByCarmelo Blanquicett, MD, PhD, FACP,Theodore Johnson, II, MD, MPH,Christopher Flowers, MD, MS,Jonathon B. Cohen, MD, MS

November 14th 2019

Geriatric assessments have now been recommended as part of the standard evaluation of an older adult considering cancer therapy.

Latest Updated Articles

The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer Patient
November 14th 2019
Polatuzumab Vedotin Regimen Yields ‘Meaningful’ Benefit in DLBCL, Expert Says
April 19th 2023

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Achieving a “Functional Cure” With Multiple Myeloma Therapy

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)